{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:11:27Z","timestamp":1792649487097,"version":"4.5.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:00:00Z","timestamp":1675900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Most patients with atherosclerotic cardiovascular disease remain at (very) high risk for recurrent events due to suboptimal risk factor control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>This study aimed to quantify the potential of maximal risk factor treatment on 10-year and lifetime risk of recurrent atherosclerotic cardiovascular events in patients 1 year after a coronary event.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Pooled data from six studies are as follows: RESPONSE 1, RESPONSE 2, OPTICARE, EUROASPIRE IV, EUROASPIRE V, and HELIUS. Patients aged \u226545 years at \u22656 months after coronary event were included. The SMART-REACH score was used to estimate 10-year and lifetime risk of recurrent atherosclerotic cardiovascular events with current treatment and potential risk reduction and gains in event-free years with maximal treatment (lifestyle and pharmacological). In 3230 atherosclerotic cardiovascular disease patients (24% women), at median interquartile range (IQR) 1.1 years (1.0\u20131.8) after index event, 10-year risk was median (IQR) 20% (15\u201327%) and lifetime risk 54% (47\u201363%). Whereas 70% used conventional medication, 82% had \u22651 drug-modifiable risk factor not on target. Furthermore, 91% had \u22651 lifestyle-related risk factor not on target. Maximizing therapy was associated with a potential reduction of median (IQR) 10-year risk to 6% (4\u20138%) and of lifetime risk to 20% (15\u201327%) and a median (IQR) gain of 7.3 (5.4\u201310.4) atherosclerotic cardiovascular disease event-free years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Amongst patients with atherosclerotic cardiovascular disease, maximizing current, guideline-based preventive therapy has the potential to mitigate a large part of their risk of recurrent events and to add a clinically important number of event-free years to their lifetime.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwad038","type":"journal-article","created":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T09:34:29Z","timestamp":1675848869000},"page":"601-610","source":"Crossref","is-referenced-by-count":17,"title":["Unexploited potential of risk factor treatment in patients with atherosclerotic cardiovascular disease"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2956-8121","authenticated-orcid":false,"given":"Tinka J","family":"van Trier","sequence":"first","affiliation":[{"name":"Department of Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam , Meibergdreef 9, 1105 AZ Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein","family":"Snaterse","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam , Meibergdreef 9, 1105 AZ Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven H J","family":"Hageman","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, University Medical Center Utrecht , Heidelberglaan 100, 3584 CX Utrecht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nienke","family":"ter Hoeve","sequence":"additional","affiliation":[{"name":"Capri Cardiac Rehabilitation Rotterdam , Max Euwelaan 55, 3062 MA Rotterdam , The Netherlands"},{"name":"Department of Rehabilitation Medicine, Erasmus Medical Centre , Dr. Molewaterplein 40, 3015 GD Rotterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madoka","family":"Sunamura","sequence":"additional","affiliation":[{"name":"Capri Cardiac Rehabilitation Rotterdam , Max Euwelaan 55, 3062 MA Rotterdam , The Netherlands"},{"name":"Department of Cardiology, Sint Franciscus Gasthuis , Kleiweg 500, 3045 PM Rotterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric P","family":"Moll van Charante","sequence":"additional","affiliation":[{"name":"Department of General Practice, Amsterdam University Medical Centers , Meibergdreef 9, 1105 AZ Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrike","family":"Galenkamp","sequence":"additional","affiliation":[{"name":"Department of Public and Occupational Health, Amsterdam Public Health Research Institute, Amsterdam University Medical Centers , Meibergdreef 9, 1105 AZ Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5275-7254","authenticated-orcid":false,"given":"Jaap W","family":"Deckers","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Thoraxcenter, Erasmus Medical Centre , Dr. Molewaterplein 40, 3015 GD Rotterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice M A C","family":"Martens","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Deventer Hospital , Nico Bolkesteinlaan 75, 7416 SE Deventer , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank L J","family":"Visseren","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, University Medical Center Utrecht , Heidelberglaan 100, 3584 CX Utrecht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilma J M","family":"Scholte op Reimer","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam , Meibergdreef 9, 1105 AZ Amsterdam , The Netherlands"},{"name":"HU University of Applied Sciences Utrecht, Research Group Chronic Diseases , Padualaan 99, 3584 CH Utrecht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron J G","family":"Peters","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam , Meibergdreef 9, 1105 AZ Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald T","family":"J\u00f8rstad","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam , Meibergdreef 9, 1105 AZ Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,2,9]]},"reference":[{"key":"2023050916271181600_zwad038-B1","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/eurheartj\/ehu505","article-title":"Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective","volume":"36","author":"Jernberg","year":"2015","journal-title":"Eur Heart J"},{"key":"2023050916271181600_zwad038-B2","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1001\/archinte.162.21.2405","article-title":"The underlying risk of death after myocardial infarction in the absence of treatment","volume":"162","author":"Law","year":"2002","journal-title":"Arch Intern Med"},{"key":"2023050916271181600_zwad038-B3","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet"},{"key":"2023050916271181600_zwad038-B4","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1136\/heartjnl-2013-303989","article-title":"Effect of a nurse-coordinated prevention programme on cardiovascular risk after an acute coronary syndrome: main results of the RESPONSE randomised trial","volume":"99","author":"Jorstad","year":"2013","journal-title":"Heart"},{"key":"2023050916271181600_zwad038-B5","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jacc.2017.05.041","article-title":"Community-based lifestyle intervention in patients with coronary artery disease: the RESPONSE-2 trial","volume":"70","author":"Minneboo","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2023050916271181600_zwad038-B6","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1177\/2047487318825350","article-title":"Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry","volume":"26","author":"Kotseva","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"2023050916271181600_zwad038-B7","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/S0140-6736(08)60868-5","article-title":"Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial","volume":"371","author":"Wood","year":"2008","journal-title":"Lancet"},{"key":"2023050916271181600_zwad038-B8","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study","volume":"28","author":"Ray","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"2023050916271181600_zwad038-B9","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.amjmed.2011.12.013","article-title":"Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients","volume":"125","author":"Naderi","year":"2012","journal-title":"Am J Med"},{"key":"2023050916271181600_zwad038-B10","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1093\/eurheartj\/ehz714","article-title":"Secondary prevention medications after coronary artery bypass grafting and long-term survival: a population-based longitudinal study from the SWEDEHEART registry","volume":"41","author":"Bjorklund","year":"2020","journal-title":"Eur Heart J"},{"key":"2023050916271181600_zwad038-B11","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1177\/2047487320904334","article-title":"Cardiovascular event rates increase after each recurrence and associate with poor statin adherence","volume":"28","author":"Lassenius","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"2023050916271181600_zwad038-B12","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N Engl J Med"},{"key":"2023050916271181600_zwad038-B13","first-page":"397","article-title":"Rivaroxaban in stable cardiovascular disease","volume":"378","author":"Eikelboom","year":"2018","journal-title":"N Engl J Med"},{"key":"2023050916271181600_zwad038-B14","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"2023050916271181600_zwad038-B15","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N Engl J Med"},{"key":"2023050916271181600_zwad038-B16","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"2023050916271181600_zwad038-B17","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1161\/CIRCULATIONAHA.117.032038","article-title":"Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study)","volume":"137","author":"Mahaffey","year":"2018","journal-title":"Circulation"},{"key":"2023050916271181600_zwad038-B18","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"2023050916271181600_zwad038-B19","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"2023050916271181600_zwad038-B20","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"2023050916271181600_zwad038-B21","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"2023050916271181600_zwad038-B22","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"2023050916271181600_zwad038-B23","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"2023050916271181600_zwad038-B24","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"2023050916271181600_zwad038-B25","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1161\/CIRCULATIONAHA.118.035289","article-title":"Conceptual framework for addressing residual atherosclerotic cardiovascular disease risk in the era of precision medicine","volume":"137","author":"Patel","year":"2018","journal-title":"Circulation"},{"key":"2023050916271181600_zwad038-B26","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3389\/fcvm.2020.00088","article-title":"The evolving understanding and approach to residual cardiovascular risk management","volume":"7","author":"Dhindsa","year":"2020","journal-title":"Front Cardiovasc Med"},{"key":"2023050916271181600_zwad038-B27","article-title":"The challenge of choosing in cardiovascular risk management","author":"Hoogeveen","year":"2021","journal-title":"Neth Heart J"},{"key":"2023050916271181600_zwad038-B28","doi-asserted-by":"crossref","first-page":"e009217","DOI":"10.1161\/JAHA.118.009217","article-title":"Estimated life expectancy without recurrent cardiovascular events in patients with vascular disease: the SMART-REACH model","volume":"7","author":"Kaasenbrood","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2023050916271181600_zwad038-B29","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1136\/heartjnl-2017-311681","article-title":"Randomised controlled trial of two advanced and extended cardiac rehabilitation programmes","volume":"104","author":"Sunamura","year":"2018","journal-title":"Heart"},{"key":"2023050916271181600_zwad038-B30","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1177\/2047487315569401","article-title":"EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries","volume":"23","author":"Kotseva","year":"2016","journal-title":"Eur J Prev Cardiol"},{"key":"2023050916271181600_zwad038-B31","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1186\/1471-2458-13-402","article-title":"Unravelling the impact of ethnicity on health in Europe: the HELIUS study","volume":"13","author":"Stronks","year":"2013","journal-title":"BMC Public Health"},{"key":"2023050916271181600_zwad038-B32","doi-asserted-by":"crossref","first-page":"e017873","DOI":"10.1136\/bmjopen-2017-017873","article-title":"Cohort profile: the Healthy Life in an Urban Setting (HELIUS) study in Amsterdam, The Netherlands","volume":"7","author":"Snijder","year":"2017","journal-title":"BMJ Open"},{"key":"2023050916271181600_zwad038-B33","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/eurheartj\/ehm316","article-title":"European Guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts)","volume":"28","author":"Graham","year":"2007","journal-title":"Eur Heart J"},{"key":"2023050916271181600_zwad038-B34","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1177\/2047487312450228","article-title":"European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts)","volume":"19","author":"Fifth Joint Task Force of the European Society of Cardiology; European Association of Echocardiography; European Association of Percutaneous Cardiovascular Interventions; European Heart Rhythm Association; Heart Failure Association; European Association for Cardiovascular Prevention & Rehabilitation; European Atherosclerosis Society; International Society of Behavioural Medicine; European Stroke Organisation; European Society of Hypertension; European Association for the Study of Diabetes; European Society of General Practice\/Family Medicine; International Diabetes Federation Europe; European Heart Network","year":"2012","journal-title":"Eur J Prev Cardiol"},{"key":"2023050916271181600_zwad038-B35","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","article-title":"2016 European guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur Heart J"},{"key":"2023050916271181600_zwad038-B36","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/oby.2004.137","article-title":"Development of health-related waist circumference thresholds within BMI categories","volume":"12","author":"Ardern","year":"2004","journal-title":"Obes Res"},{"key":"2023050916271181600_zwad038-B37","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1038\/oby.2009.44","article-title":"Clinical utility of waist circumference in predicting all-cause mortality in a preventive cardiology clinic population: a PreCIS database study","volume":"17","author":"Bajaj","year":"2009","journal-title":"Obesity (Silver Spring)"},{"key":"2023050916271181600_zwad038-B38","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jclinepi.2022.01.011","article-title":"Population median imputation was noninferior to complex approaches for imputing missing values in cardiovascular prediction models in clinical practice","volume":"145","author":"Berkelmans","year":"2022","journal-title":"J Clin Epidemiol"},{"key":"2023050916271181600_zwad038-B39","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1541-0420.2010.01420.x","article-title":"Cause-specific cumulative incidence estimation and the fine and gray model under both left truncation and right censoring","volume":"67","author":"Geskus","year":"2011","journal-title":"Biometrics"},{"key":"2023050916271181600_zwad038-B40","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1177\/2047487318798060","article-title":"Biologic bases of residual risk of cardiovascular events: a flawed concept","volume":"25","author":"Shapiro","year":"2018","journal-title":"Eur J Prev Cardiol"},{"key":"2023050916271181600_zwad038-B41","article-title":"Exercise-based cardiac rehabilitation for coronary heart disease","volume":"11","author":"Dibben","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"2023050916271181600_zwad038-B42","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/MOL.0000000000000554","article-title":"The prediction of therapy-benefit for individual cardiovascular disease prevention: rationale, implications, and implementation","volume":"29","author":"Jaspers","year":"2018","journal-title":"Curr Opin Lipidol"},{"key":"2023050916271181600_zwad038-B43","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/eurjpc\/zwab028","article-title":"Residual cardiovascular risk reduction guided by lifetime benefit estimation in patients with symptomatic atherosclerotic disease: effectiveness and cost-effectiveness","volume":"29","author":"Hageman","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"2023050916271181600_zwad038-B44","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s41512-020-00072-5","article-title":"Would treatment decisions about secondary prevention of CVD based on estimated lifetime benefit rather than 10-year risk reduction be cost-effective?","volume":"4","author":"Berkelmans","year":"2020","journal-title":"Diagn Progn Res"},{"key":"2023050916271181600_zwad038-B45","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1001\/jamacardio.2018.3680","article-title":"Influence of cardiovascular risk communication tools and presentation formats on patient perceptions and preferences","volume":"3","author":"Navar","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2023050916271181600_zwad038-B46","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-041673","article-title":"Communicating personalised statin therapy-effects as 10-year CVD-risk or CVD-free life-expectancy: does it improve decisional conflict? Three-armed, blinded, randomised controlled trial","volume":"11","author":"Jaspers","year":"2021","journal-title":"BMJ Open"},{"key":"2023050916271181600_zwad038-B47","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.amjmed.2012.01.014","article-title":"An international model to predict recurrent cardiovascular disease","volume":"125","author":"Wilson","year":"2012","journal-title":"Am J Med"},{"key":"2023050916271181600_zwad038-B48","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1161\/CIRCULATIONAHA.116.021314","article-title":"Distribution of estimated 10-year risk of recurrent vascular events and residual risk in a secondary prevention population","volume":"134","author":"Kaasenbrood","year":"2016","journal-title":"Circulation"},{"key":"2023050916271181600_zwad038-B49","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.amjcard.2020.07.046","article-title":"Risk for recurrent cardiovascular events and expected risk reduction with optimal treatment 1 year after an acute coronary syndrome","volume":"133","author":"Zafeiropoulos","year":"2020","journal-title":"Am J Cardiol"},{"key":"2023050916271181600_zwad038-B50","doi-asserted-by":"crossref","first-page":"i1548","DOI":"10.1136\/bmj.i1548","article-title":"How to translate clinical trial results into gain in healthy life expectancy for individual patients","volume":"352","author":"Dorresteijn","year":"2016","journal-title":"Bmj-British Medical Journal"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwad038\/49526663\/zwad038.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/30\/7\/601\/50258655\/zwad038.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/30\/7\/601\/50258655\/zwad038.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T22:50:52Z","timestamp":1683759052000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/article\/30\/7\/601\/7033256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,9]]},"references-count":50,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,2,9]]},"published-print":{"date-parts":[[2023,5,9]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwad038","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5,1]]},"published":{"date-parts":[[2023,2,9]]}}}